Montanova Capital LLC purchased a new position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report) during the second quarter, according to its most recent 13F filing with the SEC. The institutional investor purchased 121,297 shares of the biopharmaceutical company’s stock, valued at approximately $4,513,000.
A number of other hedge funds and other institutional investors have also recently bought and sold shares of CLDX. Wilmington Savings Fund Society FSB bought a new position in Celldex Therapeutics in the 3rd quarter valued at $42,000. Russell Investments Group Ltd. boosted its stake in Celldex Therapeutics by 27.6% in the second quarter. Russell Investments Group Ltd. now owns 2,315 shares of the biopharmaceutical company’s stock worth $47,000 after purchasing an additional 501 shares in the last quarter. Quantbot Technologies LP bought a new stake in shares of Celldex Therapeutics during the third quarter worth $63,000. Kestra Advisory Services LLC bought a new stake in shares of Celldex Therapeutics during the fourth quarter worth $98,000. Finally, Headlands Technologies LLC acquired a new stake in shares of Celldex Therapeutics in the second quarter valued at $125,000.
Celldex Therapeutics Stock Up 1.3%
Shares of CLDX opened at $39.63 on Tuesday. Celldex Therapeutics, Inc. has a 12-month low of $21.71 and a 12-month high of $45.14. The firm has a market capitalization of $3.11 billion, a PE ratio of -9.11 and a beta of 0.87. The stock’s fifty day simple moving average is $38.64 and its 200-day simple moving average is $33.43.
Analyst Ratings Changes
A number of research analysts recently issued reports on CLDX shares. Guggenheim lifted their price target on Celldex Therapeutics from $90.00 to $100.00 and gave the company a “buy” rating in a report on Monday, July 20th. Barclays raised their price objective on shares of Celldex Therapeutics from $48.00 to $53.00 and gave the company an “overweight” rating in a research report on Friday, August 7th. Cantor Fitzgerald dropped their target price on shares of Celldex Therapeutics from $67.00 to $61.00 and set an “overweight” rating for the company in a research note on Wednesday, July 22nd. HC Wainwright reiterated a “buy” rating and set a $42.00 target price on shares of Celldex Therapeutics in a research report on Monday, June 15th. Finally, Morgan Stanley increased their price target on shares of Celldex Therapeutics from $40.00 to $46.00 and gave the company an “overweight” rating in a research note on Friday, August 7th. One investment analyst has rated the stock with a Strong Buy rating, ten have assigned a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Moderate Buy” and an average target price of $56.08.
Check Out Our Latest Analysis on CLDX
Celldex Therapeutics Company Profile
Celldex Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of targeted immunotherapies for cancer and other serious diseases. The company’s research platforms leverage novel antibody and vaccine technologies designed to engage the patient’s immune system, with a particular emphasis on oncology and neurologic indications. Celldex’s pipeline includes both monoclonal antibodies and biologic agents that seek to modulate immune responses or deliver targeted cytotoxic activity.
Among Celldex’s lead product candidates is glembatumumab vedotin, an antibody–drug conjugate directed against the glycoprotein NMB (gpNMB) for the treatment of certain breast and skin cancers.
Featured Articles
- Five stocks we like better than Celldex Therapeutics
- Securing AI: 5 Most-Upgraded Stocks From the Q2 Reporting Season
- Insiders Are Betting Big on These 3 Healthcare Stocks
- 3 Stocks for Investors Who Still Believe Cash Is King
- Dollar General and Dollar Tree Are Recovering, But Not for the Same Reason
Want to see what other hedge funds are holding CLDX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Celldex Therapeutics, Inc. (NASDAQ:CLDX – Free Report).
Receive News & Ratings for Celldex Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Celldex Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
